跳至主要内容
临床试验/NCT03631576
NCT03631576Unknown2 期

CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Fujian Medical University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2018年8月10日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
20
试验地点
1
主要终点
Leukemia free survival

研究概览

简要总结

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed written informed consent
  • Aged < 70 years
  • Patients with relapsed/refractory AML
  • Cardiac: Left ventricular ejection fraction ≥ 50%
  • Adequate renal and hepatic function
  • Performance status: Karnofsky ≥ 70%

排除标准

  • Pregnant or lactating females.
  • Any co-morbidity precluding the administration of CD123/CLL1 CAR-T Cells.

结局指标

主要结局

Leukemia free survival

时间窗: 1 year

次要结局

  • Adverse events that are related to treatment(1 year)

研究者

发起方
Fujian Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jianda Hu

Director of the department of Hematology

Fujian Medical University

研究点 (1)

Loading locations...

相似试验